Britain and America have forged a important bilateral deal that will guarantee no tariffs on British drug exports entering the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase funding on pharmaceuticals through the public health system. This pledge guarantees that duties on these crucial goods will remain at zero for a period of 36 months.
This development follows previous warnings to hike import taxes on patented drug imports, with figures floated up to double the cost.
"This arrangement with the United Kingdom reinforces the worldwide climate for new treatments and brings long-overdue fairness to transatlantic medicine commerce," a release said.
Economic Importance
Drugs represent one of the UK's most significant export categories to the United States, which is clearly the primary market for major UK drugmakers.
Statistics reveal that in the one-year period prior to last September, the UK shipped pharmaceutical products totaling billions to the US. This amount made up nearly one-fifth of total UK exports in that period.
"This deal secures employment, increases capital expenditure and facilitates the UK to establish itself as a global hub for biotech and pharma," a minister remarked.
Key UK Commitments
The pact entails several key changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to increase total NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The percentage drug companies must refund to the NHS to control costs will be limited at 15%. Previously, refunds topped 20%.
Industry Background
The pact follows a long-running row between the sector and the ministers over medicine costs and approval rates.
The disagreement were exacerbated by arguments that US consumers were charged a premium for the same drugs than patients in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been paused or abandoned, while substantial expansions have been directed toward American operations.
One official stated that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had declined as a share of its resources over the last ten years.
